Latest revenue
$75.0K
as of 2024-09-30
Latest net income
$91.2K
as of 2024-09-30
Net margin
121.6%
as of 2024-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.8M
- Enterprise value
- $8.4M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $4.21
- 52-wk low
- $0.05
- Beta
- —
- Shares out
- 4.7M
Community sentiment
Where do you think PFSA is heading?
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
5-year trend
What this company does
ITEM 1. BUSINESS Overview We were originally incorporated under the name “Northview Acquisition Corp.” as a blank check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. As discussed in this Annual Report, we completed the Business Combination on July 11, 2025 and changed our name to “Profusa, Inc.” Profusa is a digital health technology company based in Berkeley, California, that has invested over the last twelve years more than $100 million from sophisticated venture investors as well as the most sophisticated…
AI summary unavailable — showing raw filing excerpt
Generated from PFSA's filing dated 2026-04-15
Key risks
ITEM 1A. RISK FACTORS Investing in our securities includes a high degree of risk. Prior to making a decision about investing in our securities, you should consider carefully the specific factors discussed below, including the matters addressed under the heading “Cautionary Note Regarding Forward-Looking Statements,” together with all of the other information contained in this Annual Report on Form 10-K (the “Annual Report”). The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on Profusa’s business, reputation, revenue, financial condition, results of…
AI summary unavailable — showing raw filing excerpt
Generated from PFSA's filing dated 2026-04-15
Profitability
Operating margin
-1057.8%
1476.5%Net margin
-2169.6%
4298.7%Return on equity
134.4%
49.6%Return on assets
-949.0%
762.8%Leverage
Debt / equity
-1.14×
66.7%Debt / assets
806.2%
470.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-3.5M | -208.6% | — |
Q4 2025 2025-12-31 | — | — | $-4.3M | +46.8% | — |
Q3 2025 2025-09-30 | — | — | $-22.2M | -24439.5% | — |
Q2 2025 2025-06-30 | — | — | $-8.2M | -1962.2% | — |
Q1 2025 2025-03-31 | — | — | $-1.1M | -36.5% | — |
Q4 2024 2024-12-31 | — | — | $-8.1M | — | — |
Q3 2024 2024-09-30 | $75.0K | — | $91.2K | +124.8% | 121.6% |
Q2 2024 2024-06-30 | — | — | $-397.5K | -146.6% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on PFSA — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for PFSA in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns PFSA
Institutional value
$3.2K
Total shares held
6.5K
Distinct holders
5
-16 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 3.9K | $2.0K | — | New |
| 2 | VANGUARD FIDUCIARY TRUST CO | 1.7K | $859 | — | New |
| 3 | UBS Group AG | 665 | $337 | -3.5M (-100.0%) | Trimmed |
| 4 | SBI Securities Co., Ltd. | 45 | $23 | -1.4K (-96.8%) | Trimmed |
| 5 | Mint Tower Capital Management B.V. | 125 | $0 | -9.2K (-98.7%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once PFSA's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.